Top 8 Viral Inactivation Firms: Global Market & Solutions 2025

The global viral inactivation market was valued at USD 686.62 million in 2024. The market is expected to grow at a CAGR of 11.5% during the forecast period of 2025-2034, with the values likely to reach USD 1,828.89 million by 2034. The market is driven by rising biologics demand, stringent regulatory guidelines, increased biopharmaceutical R&D, and growing concerns over viral contamination in therapies.

Viral inactivation is crucial for ensuring the safety of biopharmaceuticals. This process eliminates any viruses that could be present in vaccines, biologics, and blood-derived products. It employs methods such as chemicals, heat, or radiation to guarantee the safety of these products.

The viral inactivation market is expanding, driven by an increasing demand for biopharmaceuticals, strict regulatory requirements, and awareness of blood safety. Advancements in virus removal technologies and the rising use of single-use bioprocessing are propelling the market growth. Leading companies are focusing on innovation and strategic partnerships for improved viral inactivation solutions.

In June 2024, Ruvidar, a small molecule compound developed by Theralase Technologies, demonstrated its potential in inactivating enveloped and non-enveloped viruses, according to a peer-reviewed study. Its ability to inactivate coronaviruses opens new avenues for vaccine development, which is expected to spur innovation and investment in the market for viral inactivation, thereby propelling its growth.

Global Biologics Safety: 8 Leading Inactivation Companies 2025

1. Merck KGaA

Merck stands as a leading innovator in the global viral inactivation market, providing high-quality solutions that ensure viral safety in biopharmaceutical manufacturing. Its Emprove program facilitates regulatory compliance through the availability of a variety of virus inactivation techniques, such as solvent/detergent treatments and pasteurization. With a strong market presence, Merck helps boost market growth through enhancements in process efficiency, reliability, and the confidence of regulatory compliance.

2. Sartorius AG

Sartorius is a leading provider of viral inactivation solutions. The company specializes in innovative automation in biopharmaceutical manufacturing. The Flexact Modular system offers precise, scalable low pH virus inactivation, allowing for effective virus removal during the monoclonal antibodies (mAb) production process. Along with its single-use technology and integrated pH control, Sartorius improves processes, reduces costs, and sparks innovation, strengthening its position in the rapidly growing market for viral inactivation.

3. Cerus Corporation

Cerus Corporation is a leading player in the global viral inactivation market, specializing in state-of-the-art blood safety technologies. Its Intercept Blood System, commercialized in Europe and used for the inactivation of pathogens such as SARS, HIV, and hepatitis in platelets and red blood cells, has been recognized for inactivating pathogens in those portions of blood. Its improved transfusion safety is expanding its market presence and helping address the required need for effective viral inactivation solutions.

4. Charles River Laboratories

Charles River has a significant presence in the viral inactivation market globally, offering a wide variety of biologics testing solutions. The company specializes in viral clearance studies, which are critical for ascertaining the safety of biologics and medical devices by validating viral inactivation processes. With facilities in Wayne, PA, and Cologne, Germany, Charles River supports studies that comply with regulatory standards, thereby enhancing confidence in the safety of biologics in the market. Their expertise in assessing contamination risks and ensuring regulatory compliance is instrumental in driving market growth by upholding rigorous safety standards in the production of biologics.

5. Terumo Blood and Cell Technologies, Inc.

Terumo BCT is a prominent contributor to the global viral inactivation market through its Mirasol Pathogen Reduction Technolog y (PRT) system, designed to inactivate viruses, bacteria, and parasites in blood components. By employing riboflavin and UV light, Mirasol enhances the safety of transfusions by reducing the risk of viral transmission. With the increasing demand for effective viral inactivation solutions, Terumo BCT is strengthening its market position by responding to global health challenges, fostering innovation, and developing blood safety technologies.

6. Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is a leading player in the global market for viral inactivation, offering solutions that address safe virus handling in diagnostics and research. It ensures secure viral RNA collection, inactivation, and stabilization via its InhibiSURE viral inactivation medium for diagnosis. The increasing demand for reliable products for viral inactivation creates opportunities for market expansion, solidifying its leadership in the diagnostic and biopharmaceutical fields while adhering to global safety and regulatory standards.

7. Texcell SA

Texcell holds a prominent position in the global viral inactivation market. The company develops specialized viral clearance studies to ensure the safety of biotherapeutic products. For monoclonal antibodies, gene therapies, and plasma-derived products, the organization validates viral clearance. Its specialized expertise in chromatography purification along with compliance with evolving ICH regulations makes the inactivation process in viruses more effective. By leveraging its background in viral clearance, Texcell supports market growth by reducing costs and accelerating timelines for biopharmaceutical development.

8. Rad Source Technologies Inc.

Rad Source Technologies plays a significant role in the global viral inactivation market with its unique X-ray irradiation technology. The company’s solutions facilitate the safe and effective inactivation of viruses by selectively damaging their genetic material, which is essential for vaccine development. With a robust presence in biopharmaceutical research, Rad Source Technologies is driving market growth by offering non-nuclear ionizing radiation methods for viral inactivation.